- Home
- FISI vs SLDB Comparison
FISI vs SLDB Comparison
Compare FISI & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FISI | SLDB |
|---|---|---|
| Founded | 1817 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.4M | 781.7M |
| IPO Year | 1999 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FISI | SLDB |
|---|---|---|
| Price | $39.67 | $7.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $45.00 | $18.62 |
| AVG Volume (30 Days) | 105.8K | ★ 1.2M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | ★ 231.27 | 34.97 |
| EPS | ★ 2.08 | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $6.51 | N/A |
| Revenue Next Year | $4.63 | N/A |
| P/E Ratio | $18.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.61 | $3.79 |
| 52 Week High | $42.97 | $11.45 |
Technical Indicators
Market Signals| Indicator | FISI | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 31.35 |
| Support Level | $37.78 | $6.25 |
| Resistance Level | $40.33 | $7.26 |
| Average True Range (ATR) | 0.80 | 0.44 |
| MACD | -0.11 | -0.17 |
| Stochastic Oscillator | 51.52 | 15.71 |
Price Performance
Historical ComparisonAbout FISI Financial Institutions Inc.
Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.